Compare CELH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELH | SRRK |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.8B |
| IPO Year | 2008 | 2018 |
| Metric | CELH | SRRK |
|---|---|---|
| Price | $28.02 | $42.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 18 |
| Target Price | $42.19 | ★ $70.44 |
| AVG Volume (30 Days) | ★ 5.8M | 2.3M |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $1,318,014,000.00 | N/A |
| Revenue This Year | $26.05 | N/A |
| Revenue Next Year | $8.51 | $1,978.85 |
| P/E Ratio | $58.30 | ★ N/A |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $23.56 | $27.07 |
| 52 Week High | $66.74 | $61.76 |
| Indicator | CELH | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 29.95 |
| Support Level | $27.23 | $39.69 |
| Resistance Level | $30.19 | $48.59 |
| Average True Range (ATR) | 0.99 | 2.28 |
| MACD | 0.03 | -0.62 |
| Stochastic Oscillator | 39.92 | 13.19 |
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.